Van Campen Liem has advised uniQure B.V. in connection with its initial public offering of 5,400,000 ordinary shares at an initial public offering price of $17.00 per ordinary share and the option granted to the underwriters to purchase up to an additional 810,000 ordinary shares from uniQure.
uniQure is a leader in the field of gene therapy and had developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. Gene therapy offers the prospect of long-term and potentially curative benefit to patients with genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.
The Van Campen Liem team included Gesina van de Wetering, Edwin Liem, Cees Kersten and Shireen Raza.
For more information, please visit:Official Press Release